KDA GROUP DEPLOYS MEDHERIZE ACROSS COMMUNITY PHARMACIES: A MAJOR STEP FORWARD IN THE MANAGEMENT OF ORAL ANTICANCER THERAPIES
MWN-AI** Summary
KDA Group Inc. (TSXV: KDA), a prominent innovator in healthcare technology, has announced the significant expansion of its Medherize platform into community pharmacies across Canada. This rollout follows successful implementation at the CHU de Québec, where the platform is already tracking nearly 200 patients undergoing oral anticancer therapies (OAMs). The integration at community pharmacies, including those associated with Horizon Santé and Jean Coutu, marks an essential development in the management and monitoring of cancer treatments.
Medherize enables a seamless connection among oncologists, pharmacists, and patients, facilitating structured and continuous monitoring of treatment. This deployment aligns with the provincial framework established by the Ministère de la Santé et des Services sociaux, which aims to optimize pharmacy practices involving OAMs. The framework mandates pharmacists to assess clinical statuses, manage treatment-related issues, and ensure patient continuity of care, tasks that Medherize is designed to support effectively.
With Medherize, pharmacists receive immediate access to the therapeutic plans outlined by oncologists, along with real-time laboratory results through the Dossier Santé Québec (DSQ). This capacity allows pharmacists to monitor treatment compliance, address adverse effects promptly, and coordinate care with hospital teams. Jérôme Lavoie, President of Groupe Horizon Santé, expressed that Medherize represents a breakthrough for pharmacy operations and patient safety, while Quebec City pharmacist Pierre-Olivier Sirois emphasized its necessity for enhancing OAM follow-up.
Marc Lemieux, CEO of KDA, highlighted the platform's role in fostering a collaborative healthcare environment and revealed plans for further deployment in hospitals and pharmacies. As a pioneering interprofessional platform, Medherize aims to improve therapeutic adherence and enhance patient health outcomes, signifying a major step forward in cancer care management.
MWN-AI** Analysis
KDA Group Inc.'s recent rollout of the Medherize platform across community pharmacies is a significant development in the management of oral anticancer therapies. This initiative aligns KDA with a growing trend towards digital integration in healthcare, particularly in oncology. By connecting oncologists, pharmacists, and patients, the Medherize platform aims to enhance treatment adherence, monitor patient outcomes, and mitigate adverse effects more effectively than traditional methods.
Investors should view this deployment as a robust catalyst for growth. First, KDA’s alignment with the new provincial framework for oral anticancer medications positions it favorably against competitors, as community pharmacies adopt standardized practices that Medherize supports. This not only elevates the platform’s relevance but also enhances its marketability and acceptance among healthcare providers.
Furthermore, the technological integration allows for real-time monitoring and data sharing, which is crucial in managing complex treatment regimens. Pharmacists can now intervene promptly to manage patient concerns, thereby reinforcing their role in the treatment continuum. This seamless communication is expected to improve patient outcomes and drive increased usage of the Medherize platform—a potential boon for revenue growth.
Moreover, as healthcare continues to shift towards more integrated, tech-driven solutions, KDA is strategically positioned to capitalize on this trend. The nature of the SaaS model allows for scalable deployment, which means as more pharmacies adopt Medherize, KDA can rapidly expand its user base and revenue streams without substantial incremental costs.
In conclusion, KDA Group represents a compelling investment opportunity in the healthcare technology sector. Stakeholders should closely monitor the success of Medherize’s deployment as positive patient outcomes and increased pharmacy adoption could significantly enhance the company’s market position and financial performance moving forward.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Canada NewsWire
THETFORD MINES, QC, Dec. 1, 2025 /CNW/ - KDA Group Inc. (TSXV: KDA) ("KDA" or the "Corporation"), a leader in innovative technological solutions for healthcare professionals, is pleased to announce a major new phase in the national rollout of its Medherize platform. After deployment at the CHU de Québec, Hôpital du Saint-Sacrement, where nearly 200 patients are already being monitored through the application, Medherize is now being deployed in community pharmacies, including those affiliated with the Horizon Santé banner as well as in a pharmacy in Quebec City affiliated with the Jean Coutu banner. This marks a pivotal moment, as oncologists, patients, and now pharmacists are connected through a single digital platform that enables structured, continuous, and secure monitoring of oral anticancer treatments.
Fully aligned with the provincial framework for oral anticancer medications ("OAMs"). The Ministère de la Santé et des Services sociaux recently published a new framework aimed at optimizing community pharmacy practices for OAMs. It requires pharmacists to evaluate the patient's clinical status and analyze therapies using available lab results, provide complete patient counseling and follow-up planning, detect and manage treatment-related issues including adverse effects, and ensure continuity of care with other healthcare professionals.
Medherize was specifically designed to support these obligations. With its arrival in community pharmacies, these establishments are now fully integrated into the digital ecosystem for oral therapy monitoring. The platform provides pharmacists with direct access to the therapeutic plan established by the oncologist and automatically retrieves, via the Dossier Santé Québec (DSQ), the patient's laboratory results, including electrocardiograms (ECGs).
Pharmacists can track patient-reported adverse effects in real time, rapidly detect adherence gaps and intervene without delay, collaborate continuously with hospital teams, and secure both dispensing and renewal of OAMs. Through this integration, Medherize positions itself at the center of the modern process for dispensing and monitoring oral anticancer therapies.
Jérôme Lavoie, President of Groupe Horizon Santé (22 pharmacies), stated: "Medherize is a true breakthrough for our pharmacies and our patients. It enables highly rigorous monitoring, allows us to anticipate adverse effects, and helps us intervene at exactly the right moment. This tool strengthens our central role in the care trajectory for oral anticancer treatments."
Pierre-Olivier Sirois, Pharmacist-Owner, Jean Coutu (Quebec City), added: "Medherize has become indispensable. By connecting the pharmacy to hospital data and real-time patient information, we gain precision, speed, and safety. It is exactly the intuitive, efficient tool we needed to enhance OAM follow-up and support patients through the complexity of these treatments."
Marc Lemieux, Chief Executive Officer and Chairman of the Board of KDA, said: "The Medherize platform is the result of years of work, clinical collaboration, and sustained innovation. Seeing physicians, pharmacists, and patients united through a single platform brings our vision to life. We are particularly enthusiastic about deploying Medherize as early as January in additional hospital centers and community pharmacies that are eagerly awaiting its integration into their oncology departments. Our mission remains to provide a simple, powerful, and secure tool that improves treatment adherence and ultimately enhances patient health."
A complete care continuum. With the integration of community pharmacies, the care loop is now complete: oncologists, pharmacists, and patients are fully connected through Medherize, ensuring fluid, proactive continuity of care aligned with Quebec's new OAM requirements. Medherize is now the first fully interprofessional platform in Quebec, enabling coordinated monitoring, early intervention, structured information-sharing, and improved therapeutic adherence.
ABOUT KDA GROUP
KDA Group is a leader in technological innovations and specialized software solutions (SaaS – Software as a Service) for the healthcare professionals' market. KDA is a corporation that offers high-quality products and has recognized and respected expertise among the various stakeholders in the pharmaceutical and medical sectors. The technology products developed by KDA aim, among other things, to accelerate the healthcare's digital transformation, and are available for the Canadian and international markets. Additional information about the Corporation is available at www.groupkda.com and on SEDAR+ at www.sedarplus.ca.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release from KDA Group contains forward-looking statements. Forward-looking statements are typically identified by the words assumption, goal, guidance, objective, outlook, strategy, target, and other similar expressions, or future or conditional verbs such as aim, anticipate, believe, predict, could, expect, intend, may, plan, seek, should, strive, and will. By their nature, forward-looking statements require us to make estimates and assumptions and express opinions based on current conditions and anticipated developments, as well as other factors that Management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. KDA Group cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
SOURCE KDA Group Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/December2025/01/c5403.html
FAQ**
How does KDA Group Inc. KDA:CC plan to support community pharmacies in adapting to the integration of the Medherize platform for monitoring oral anticancer therapies?
What metrics or outcomes does KDA Group Inc. KDA:CC expect to see as a result of deploying Medherize in community pharmacies, particularly regarding patient adherence and safety?
Can KDA Group Inc. KDA:CC elaborate on how the Medherize platform ensures compliance with Quebec's new OAM requirements and facilitates communication between oncologists, pharmacists, and patients?
What future expansions or enhancements does KDA Group Inc. KDA:CC envision for the Medherize platform beyond the current community pharmacy deployment?
**MWN-AI FAQ is based on asking OpenAI questions about Kda Group Inc. (TSXVC: KDA:CC).
NASDAQ: KDA:CC
KDA:CC Trading
-4.55% G/L:
$0.105 Last:
2,500 Volume:
$0.11 Open:
